In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alastair Hay, Vice President of Peptides at Almac Sciences.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alastair, covering:
The story behind Almac’s early bet of getting into the peptide game
Behind the scenes of the incredible growth journey of Almac from a few hundred to 7000+ people... and some insight into the secret sauce behind the success
Rising demand for peptides and what makes them so attractive and valuable for various emerging therapeutic areas
Some of the challenges in developing and manufacturing peptide-based therapeutics include environmental impact

Alastair graduated with a Ph.D. in synthetic organic chemistry from the University of Edinburgh in 1998, following his first degree in Pure and Applied Chemistry at the University of Strathclyde.
He spent 12 years on the operational side of Almac’s peptide business, heading up the non-GMP custom synthesis group and then the GMP process development group. In 2015, Alastair moved on from an operational role to provide technical support on peptide projects for Almac’s global business development team.
In 2020, Alastair took on operational responsibilities, first re-assuming leadership of the Process Development department and then ultimately being appointed Vice President, Peptides in 2021.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in the life sciences.